TY - JOUR
T1 - Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?
AU - Lankester, Arjan C.
AU - Locatelli, Franco
AU - Bader, Peter
AU - Rettinger, Eva
AU - Egeler, Maarten
AU - Katewa, Satyendra
AU - Pulsipher, Michael A.
AU - Nierkens, Stefan
AU - Schultz, Kirk
AU - Handgretinger, Rupert
AU - Grupp, Stephan A.
AU - Boelens, Jaap Jan
AU - Bollard, Catherine M.
PY - 2015
Y1 - 2015
N2 - Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative approach for many pediatric patients with hematologic malignancies and some nonmalignant disorders, some critical obstacles remain to be overcome, including relapse, engraftment failure, graft-versus-host disease (GVHD), and infection. Harnessing the immune system to induce a graft-versus-tumor effect or rapidly restore antiviral immunity through the use of donor lymphocyte infusion (DLI) has been remarkably successful in some settings. Unfortunately, however, the responses to DLI can be variable, and GVHD is common. Thus, manipulations to minimize GVHD while restoring antiviral immunity and enhancing the graft-versus-tumor effect are needed to improve outcomes after allogeneic HSCT. Cellular therapies, defined as treatment modalities in which hematopoietic or nonhematopoietic cells are used as therapeutic agents, offer this promise for improving outcomes post-HSCT. This review presents an overview of the field for pediatric cell therapies in the transplant setting and discusses how we can broaden applicability beyond phase I.
AB - Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative approach for many pediatric patients with hematologic malignancies and some nonmalignant disorders, some critical obstacles remain to be overcome, including relapse, engraftment failure, graft-versus-host disease (GVHD), and infection. Harnessing the immune system to induce a graft-versus-tumor effect or rapidly restore antiviral immunity through the use of donor lymphocyte infusion (DLI) has been remarkably successful in some settings. Unfortunately, however, the responses to DLI can be variable, and GVHD is common. Thus, manipulations to minimize GVHD while restoring antiviral immunity and enhancing the graft-versus-tumor effect are needed to improve outcomes after allogeneic HSCT. Cellular therapies, defined as treatment modalities in which hematopoietic or nonhematopoietic cells are used as therapeutic agents, offer this promise for improving outcomes post-HSCT. This review presents an overview of the field for pediatric cell therapies in the transplant setting and discusses how we can broaden applicability beyond phase I.
KW - Adoptive cellular therapy
KW - Stem cell transplantation
KW - Pediatrics
KW - Chimeric antigen receptor
KW - Adoptive cellular therapy
KW - Stem cell transplantation
KW - Pediatrics
KW - Chimeric antigen receptor
UR - http://hdl.handle.net/10807/228520
U2 - 10.1016/j.bbmt.2014.07.018
DO - 10.1016/j.bbmt.2014.07.018
M3 - Article
SN - 1083-8791
VL - 21
SP - 402
EP - 411
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
ER -